GSK agreed to acquire Rapt Therapeutics for $2.2 billion to gain global rights to ozureprubart, an anti‑IgE antibody candidate being developed as a less‑frequent dosing alternative for food allergy prophylaxis. The deal values Rapt at $58 per share and gives GSK rights outside China, where the asset remains with Jemincare’s subsidiary. GSK said it will press toward phase 3 after a 2027 phase 2 readout and highlighted the potential for 12‑week dosing versus more frequent injections. Tony Wood, GSK’s CSO, framed the acquisition as consistent with the company’s strategy to buy validated targets addressing clear unmet needs.